Business Wire

CA-VELODYNE-LIDAR,-INC.

Share
Clearpath Brings Velodyne Lidar Technology to Robotics Community as Value-Added Partner

Velodyne Lidar, Inc. today announced Clearpath Robotics has become a value-add partner to offer its groundbreaking lidar sensors for the Clearpath research robot platform. Clearpath Robotics, headquartered in Canada, offers Velodyne sensors to academic and corporate research organizations on its mobile robots for survey and inspection, oil and gas, agriculture, materials handling and other applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005148/en/

Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology , which boasts industry-leading resolution, range, and field of view. Velodyne sensors create a 360° real-time map of the environment, allowing the robot to detect and avoid obstacles for safe autonomous navigation.

“Velodyne delivers outstanding contributions to the robotics research community by providing reliable, high-quality 3D lidar,” said Julian Ware, General Manager of Clearpath Robotics. “We have been recommending and integrating Velodyne products on our robotic platforms for almost a decade. Velodyne sensors have proven to handle challenging automation tasks and flawlessly function in unfamiliar and unpredictable settings.”

Velodyne’s lidar sensors are designed for seamless integration with robotic platforms by being easy to mount, having low-power consumption, and including a web configuration tool. They are meticulously designed to perform in high-stress environmental conditions like inclement weather, which is essential for outdoor deployments. Velodyne provides comprehensive documentation and support for integration in all applications.

Clearpath provides value-added services for Velodyne with wide-ranging expertise integrating its sensors in customized robotics systems. The company has extensive experience supporting Robot Operating System (ROS)-ready mobile robotics platforms by developing and maintaining ROS drivers, and providing step-by-step ROS tutorials . Velodyne sensors, which have built-in ROS integration, are available via the Clearpath Store .

“Clearpath provides a research robot platform, equipped with Velodyne sensors, that is easy to use, easy to buy, and easy to get started with development,” said Mike Jellen, President and CCO, Velodyne Lidar. “Clearpath brings the skill set and experience necessary to help customers derive maximum value from high-resolution, 3D data provided by Velodyne lidar to create innovative ground-based mobile robot solutions.”

About Clearpath Robotics

Clearpath Robotics is a global leader in unmanned vehicle robotics for research and development, and provides hardware, software, and services to enable self-driving vehicle development, deployment, and operation. Clearpath works with over 500 of the world’s most innovative brands in over 40 countries, serving markets that span industrial materials handling, mining, military, agriculture, aerospace, and academia. Clearpath is an award-winning company with recent awards, including Robotics Business Review Top 50 Company, Edison Award for Innovation, Business Insider Top 40 under 40, and Canada’s Top 100 Employers. Visit Clearpath Robotics at www.clearpathrobotics.com .

About Velodyne Lidar

Velodyne provides the smartest, most powerful lidar solutions for autonomy and driver assistance. Founded in 1983 and headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. In 2005, Velodyne’s Founder and CEO, David Hall , invented real-time surround view lidar systems, revolutionizing perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™ , the versatile Ultra Puck™ , the perfect for L4-L5 autonomy Alpha Puck™ , the ultra-wide angle VelaDome™ , the ADAS-optimized Velarray™ , and the groundbreaking software for driver assistance, Vella™ . To learn more about lidar, please visit Velodyne’s Lidar 101 webpage .

Contact:

Sean Dowdall Landis Communications Inc. for Velodyne Lidar, Inc. (415) 286-7121 velodyne@landispr.com

Christopher Bogdon Marketing Manager, Clearpath Robotics (519) 513-2416, x707 press@clearpathrobotics.com

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye